Financial Perspectives’s Supernus Pharmaceuticals SUPN Stock Holding History

Financial Perspectives’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.42K	Hold	52	–	–	﹤0.01%	643
2026 Q1	$2.69K	Hold	52	–	–	﹤0.01%	629
2025 Q4	$2.58K	Hold	52	–	–	﹤0.01%	630
2025 Q3	$2.48K	Hold	52	–	–	﹤0.01%	624
2025 Q2	$1.64K	Hold	52	–	–	﹤0.01%	640
2025 Q1	$1.7K	Hold	52	–	–	﹤0.01%	634
2024 Q4	$1.88K	Hold	52	–	–	﹤0.01%	629
2024 Q3	$1.62K	Hold	52	–	–	﹤0.01%	606
2024 Q2	$1.39K	Hold	52	–	–	﹤0.01%	600
2024 Q1	$1.77K	Hold	52	–	–	﹤0.01%	581
2023 Q4	$1.5K	Hold	52	–	–	﹤0.01%	609
2023 Q3	$1.43K	Hold	52	–	–	﹤0.01%	620
2023 Q2	$1.56K	Hold	52	–	–	﹤0.01%	600
2023 Q1	$1.88K	Hold	52	–	–	﹤0.01%	580
2022 Q4	$1.85K	Hold	52	–	–	﹤0.01%	587
2022 Q3	$1.76K	Hold	52	–	–	﹤0.01%	589
2022 Q2	$1.5K	Hold	52	–	–	﹤0.01%	612
2022 Q1	$1.68K	Hold	52	–	–	﹤0.01%	622
2021 Q4	$1.52K	Hold	52	–	–	﹤0.01%	600
2021 Q3	$1.39K	Hold	52	–	–	﹤0.01%	606
2021 Q2	$1.6K	Hold	52	–	–	﹤0.01%	619
2021 Q1	$1.36K	Hold	52	–	–	﹤0.01%	598
2020 Q4	$1.31K	Hold	52	–	–	﹤0.01%	565
2020 Q3	$1.08K	Hold	52	–	–	﹤0.01%	527
2020 Q2	$1.24K	Hold	52	–	–	﹤0.01%	507
2020 Q1	$935	Sell	52 -51	-50%	-$1.07K	﹤0.01%	493
2019 Q4	$2.44K	Buy	+103	New	+$2.5K	﹤0.01%	442

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Financial Perspectives's SUPN Position: Q2 2026 in Review

Financial Perspectives held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 52 shares worth $2.42K. The position accounts for ﹤0.01% of the portfolio, ranked #643.

Financial Perspectives first reported a position in SUPN in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.69K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Financial Perspectives held 52 shares of Supernus Pharmaceuticals worth $2.42K as of Q2 2026.
Financial Perspectives left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Financial Perspectives's portfolio in Q2 2026, its #643 holding.
Financial Perspectives first reported a position in Supernus Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
Financial Perspectives's Supernus Pharmaceuticals position peaked at $2.69K in Q1 2026.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Financial Perspectives's 13F filing for Q2 2026, filed 24 Jul 2026.